

NOVADEL PHARMA INC
Form 8-K
June 09, 2011

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 6, 2011

NOVADEL PHARMA INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

001-32177
(Commission File No.)

22-2407152
(I.R.S. Employer
Identification No.)

1200 Route 22 East, Suite 2000
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)

(908) 203-4640
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

On June 6, 2011, Craig A. Johnson, Senior Vice President, Chief Financial Officer and Secretary of NovaDel Pharma Inc. (the "Company"), informed the Board of Directors of the Company that he intends to resign from his positions with the Company effective July 31, 2011. Mr. Johnson has served as the Company's Senior Vice President, Chief Financial Officer and Secretary since June 2010. There is no disagreement between Mr. Johnson and the Company on any matter relating to the Company's operations, policies or practices.

On June 8, 2011, the Board of Directors of the Company appointed Steven B. Ratoff, the Company's Chief Executive Officer, as Interim Chief Financial Officer and Secretary effective August 1, 2011.

A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit Description
No.

99.1 Press Release of NovaDel Pharma Inc. dated
June 9, 2011, entitled "NovaDel
Announces Changes in Management."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma
Inc.

By: /s/
STEVEN
B.
RATOFF

Name: Steven B.
Ratoff

Title: President
and Chief
Executive
Officer

Date: June 9, 2011
